Hostname: page-component-7b7567c8c-m6dxt Total loading time: 0 Render date: 2026-11-18T22:08:28.517Z Has data issue: false hasContentIssue false

Can we Tackle the Antibiotic Threat?

Published online by Cambridge University Press:  09 February 2016

Jos W.M. Van Der Meer
Affiliation:
Department of Medicine, Radboud University Medical Centre, PO Box 9101, 6500HB Nijmegen, the Netherlands. E-mail: Jos.vanderMeer@radboudumc.nlEuropean Academies Science Advisory Council (EASAC), c/o Leopoldina, Halle Germany
Robin Fears
Affiliation:
European Academies Science Advisory Council (EASAC), c/o Leopoldina, Halle Germany
Volker Ter Meulen
Affiliation:
European Academies Science Advisory Council (EASAC), c/o Leopoldina, Halle Germany
Rights & Permissions [Opens in a new window]

Abstract

Information

Type
Erasmus Lecture 2014
Copyright
© Academia Europaea 2016 
Figure 0

Figure 1The time line of antimicrobial drug discovery and the emergence of resistant microorganisms. For the various antimicrobial drugs only the approximate year of discovery of the prototype is indicated. That means that all the numerous derivatives of, for instance, the penicillins and cephalosporins are not depicted. R means resistance. ESBL=Extended-spectrum beta-lactamase; VRE=Vancomycin-resistant enterococcus; VISA=Vancomycin-intermediate resistant Staphylococcus aureus; VRSE=Vancomycin-resistant Staphylococcus epidermidis; KC=Klebsiella carbapenemase; NDM-1=New Delhi Metallo-beta-lactamase.

Figure 1

Table 1The most important resistant microorganisms.

Figure 2

Table 2Recommendations from EASAC to EU.

Figure 3

Figure 2Problems and solutions in antimicrobial drug discovery and development.